Abstract 781P
Background
Precision medicine for cancer patients has brought effective novel therapy options over the past decades. However, treatment for high-risk ovarian cancer is still based on platinum containing chemotherapy. Around 30% of primary disease patients do not respond, and 40% of complete responders relapse within a year. Strong predictive markers are lacking. This study reports a predictive chemotherapy sensitivity score to support patient-centred and better informed treatment decisions.
Methods
89 ovarian cancer patients eligible for chemotherapy were included in the trial between 2019 and 2022 in the Netherlands (IRB P18.032). Tumour clusters were isolated from ascites and solid tumour, seeded into a 384-well plate, and exposed to carboplatin, paclitaxel, three second-line chemotherapies, PARPi, and six immunotherapies. Next, ex vivo drug sensitivity was quantified using high-throughput 3D imaging and extraction of morphological features. The chemotherapy sensitivity score was generated by correlation of the assay results with the patients' response to carboplatin-paclitaxel. In parallel, patients’ relative sensitivity to other chemo-, targeted- and immunotherapies was assessed.
Results
The platform enabled accurate prediction of carboplatin-paclitaxel with a classification accuracy of 80%. Differential ex vivo patient response profiles were observed across second-line therapies, and 11% of the samples demonstrated a strong response to at least one of the immune compounds, indicating that our test method could provide alternative treatment options. For doxorubicin, the ex vivo results match clinical response (n=3), providing further evidence for the predictivity of the assay. Importantly, the assay has a success rate of 89%.
Conclusions
The prediction of clinical response to first-line therapy and identification of patient-specific sensitivity to ten second-line therapies in parallel, allows the support of informed treatment decisions for multiple treatment classes. Its two-week timeline makes the assay applicable in a clinical environment. A prospective trial for patients with suboptimal response and recurrent disease is ongoing.
Clinical trial identification
CME LUMC-P18.032.
Editorial acknowledgement
Legal entity responsible for the study
Leiden University Medical Center Radboud University Medical Center.
Funding
VitroScan B.V.
Disclosure
C.D. de Kroon: Other, Personal, Local PI: LUMC. A. van Altena: Other, Personal, Local PI: Radboud UMC. D. van der Meer, L. Ceton, J. van der Valk, T. Sijsenaar: Financial Interests, Personal, Full or part-time Employment: VitroScan. F. Grillet, M. Garcia Montero: Non-Financial Interests, Personal, Non-financial benefits: VitroScan. W. Vader: Financial Interests, Personal, Stocks or ownership: VitroScan; Financial Interests, Personal, Full or part-time Employment: VitroScan. P.B. Ottevanger: Non-Financial Interests, Personal, Local PI: Radboud UMC. J.R. Kroep: Non-Financial Interests, Personal, Local PI: LUMC.
Resources from the same session
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11
769P - Pharmacokinetic boosting of olaparib: An open-label, prospective, cross-over study
Presenter: Joanneke Overbeek
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11